Money raised in the round came through the sale of 2.4 million shares of its common stock at a price of $1.80 per share, the New York City-based company said.
The offering also includes a 45-day underwriter’s option to purchase an additional 362,292 shares of common stock to cover any overallotments, Pavmed said.
Dawson James Securities acted as the sole underwriter for the offering.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.